Igniting the
power of
promising science
to unleash new possibilities for patients
Latest News
September 17, 2019
SpringWorks Therapeutics Announces Closing Of Initial Public Offering and Exercise in Full of the Underwriter’s Option to Purchase Additional Shares
Read More
September is Desmoid Tumor Awareness Month
SpringWorks is proud to join the Desmoid Tumor Research Foundation (DTRF) in celebrating Desmoid Tumor Awareness Month.
Although desmoid tumors are rare, they are often debilitating, disfiguring and can cause significant morbidities, including severe pain, impaired mobility and internal bleeding. This September, we unite with the DTRF to raise awareness and support ongoing research that could lead to new treatment options. Together, we can make a difference for the people living with desmoid tumors.
Our Focus
We pioneer efficient pathways for drug development for patients with severe rare diseases and cancer.
Desmoid Tumors
Desmoid tumors are rare and debilitating soft-tissue tumors that can occur in both children and adults, and that can cause severe morbidities such as pain, internal bleeding, disfigurement and limited range of motion. SpringWorks is developing a gamma secretase inhibitor for the treatment of desmoid tumors.
Neurofibromatosis Type 1
NF1 is a rare genetic disorder caused by mutations in the NF1 gene that affects both children and adults. Throughout their lifetime, a large proportion of NF1 patients progress to a more severe form of the disease that results in the development of plexiform neurofibromas (PN), which are progressive peripheral nerve sheath tumors that cause severe pain, disfigurement, debilitating loss of range of motion, and can significantly shorten lifespan. SpringWorks is developing a MEK 1/2 inhibitor inhibitor for NF1-PN.
Desmoid Tumors
Desmoid tumors are rare and debilitating soft-tissue tumors that can occur in both children and adults, and that can cause severe morbidities such as pain, internal bleeding, disfigurement and limited range of motion. SpringWorks is developing a gamma secretase inhibitor for the treatment of desmoid tumors.
Neurofibromatosis Type 1
NF1 is a rare genetic disorder caused by mutations in the NF1 gene that affects both children and adults. Throughout their lifetime, a large proportion of NF1 patients progress to a more severe form of the disease that results in the development of plexiform neurofibromas (PN), which are progressive peripheral nerve sheath tumors that cause severe pain, disfigurement, debilitating loss of range of motion, and can significantly shorten lifespan. SpringWorks is developing a MEK 1/2 inhibitor inhibitor for NF1-PN.
Our Values
Care Hard
We take caring very seriously. We care about our patients deeply, intensely, and relentlessly. Every day, we care for patients by working harder to develop solutions others haven’t.
Ambition Without Ego
We exist to ignite the power of promising science to unleash new possibilities for patients. To make this audacious ambition a reality, we must not let personal pride, empty rhetoric or ego get in the way.
Think Deeply, Act Quickly
Our team is measured, comprehensive, and thoughtful about every move we make, but we’re also driven by a sense of urgency because we know that patients are waiting. We delicately and expertly balance thinking and acting while always upholding our commitment to the highest standards of ethics and integrity.
Good Enough is Never Enough
“Good enough” is never enough for the patients and families counting on us. That’s why we constantly push ourselves to become smarter, better, and faster in pursuit of our ambition.
In It Together
We’re a team, first and foremost. Each and every SpringWorker is all in with their coworkers, partners and patients. We do our best work when we all get together, hurling jokes and big ideas and collectively making it happen.
Our Partners
Building strong partnerships with patient advocacy groups, innovators in industry and academia, and investors so that together, we can unlock the potential of science and bring new therapies to underserved patients.
Our Team
SpringWorks offers the best of both worlds — we’re a startup with a head start. We operate with the agility and flexibility of a startup, but are growing rapidly as we advance late-stage clinical trials for patients with severe rare diseases.
